Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge

The introduction of checkpoint inhibitors provided remarkable achievements in several solid tumors but only 5% of metastatic colorectal cancer (mCRC) patients, i.e., those with bearing microsatellite instable (MSI-high)/deficient DNA mismatch repair (dMMR) tumors, benefit from this approach. The fav...

Descripción completa

Detalles Bibliográficos
Autores principales: Marmorino, Federica, Boccaccino, Alessandra, Germani, Marco Maria, Falcone, Alfredo, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465130/
https://www.ncbi.nlm.nih.gov/pubmed/32824490
http://dx.doi.org/10.3390/cancers12082317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465130/
https://www.ncbi.nlm.nih.gov/pubmed/32824490
http://dx.doi.org/10.3390/cancers12082317

Ejemplares similares